QualityStocks News - International Stem Cell (ISCO) Announces Discovery of New Protein-Based Stem Cell Technology

Technology to provide ISCO with future out-licensing opportunities to the biotechnology and pharmaceutical industries

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
...proteins can be sold into the market for cellular proteins which exceeds $700 million...

Scottsdale, Arizona (PRWEB) June 15, 2012

QualityStocks would like to highlight International Stem Cell Corporation, a publicly traded company focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).

In the company’s news yesterday,

International Stem Cell Corp. announced that its wholly-owned subsidiary, Lifeline Cell Technology (LCT), has developed a technology to modify human stem cells by using engineered proteins, called “transducible transcription factors” or “TTFs.” TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types. This technology can be both therapeutically useful and be used as revenue-generating research products.

Unlike more traditional cell therapy methods, this new technology does not require the use of viruses or chemicals. Furthermore, the TTF proteins are naturally eliminated by the cells when no longer required, a characteristic that further improves safety.

Once perfected, the company first intends to use this technology to create revenue-generating research products for sale through Lifeline Cell Technology’s international distribution channels to the academic, biotechnology, and pharmaceutical markets for cellular proteins. The company will also target the quickly growing markets for the study of stem cell biology and drug testing.

According to Jeffrey Janus, Lifeline Cell Technology’s CEO, “These proteins can be sold into the market for cellular proteins which exceeds $700 million and represents an excellent opportunity for LCT to grow sales. Since the technology also has broad application in research and therapy, it should provide the company with future out-licensing opportunities to the biotechnology and pharmaceutical industries.”

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net

To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage

To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks

Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Contact